Episode 624: PCSK9 Inhibitors: Cardiovascular prevention panacea or pricey pokes?
In episode 624, James and Mike K invite Tony Nickonchuk to go over all the new evidence we have for the PCSK9 inhibitors. First, we discuss whether or not the evidence addresses the issue of primary versus secondary prevention. We then give you all the numbers and the context you need to allow you to discuss these with your patients.
Show Notes
Tools For Practice
PCSK9 Inhibitors: Cardiovascular prevention panacea or pricey pokes?
